Figure 1.

Levels of PIK3CB/PI3Kβ are the highest among the four PI3K kinases in GBM regardless of MGMT status

RNA-seq data were retrieved from DepMap, TCGA, CGGA, and THPA.

(A) Comparison of PI3K mRNAs in DepMap glioma cell lines. Cell lines from DepMap were reannotated (see Table S1). mRNA levels of PI3K kinases were compared between DepMap grade II/III (GII/III) cell lines and GBM cell lines or between MGMT-deficient and MGMT-positive cells.

(B) Comparison of PI3K mRNAs between TCGA GII/III and GBM tumors or between MGMT-deficient and MGMT-positive tumors.

(C) Comparison of PI3K mRNAs in CGGA gliomas.

(D) Immunohistochemical (IHC) staining of PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ, or MGMT in a THPA MGMT-deficient HGG (Patient ID: 1587). Details of IHC staining are shown in the inset figures. Staining levels determined by the THPA are shown in each image.

(E) Quantification of PI3Kα, PI3Kβ, PI3Kδ, or PI3Kγ based on images shown in D using ImageJ. Four persons performed ImageJ quantification independently. Each data point stands for an intensity reading from one individual.

(F) Quantification of PI3Kα, PI3Kβ, PI3Kδ, or PI3Kγ in THPA HGG or LGG tumors. Four persons performed quantification using ImageJ. Averages of intensity readings from four persons consist of individual data points. Case numbers (N) are shown. Error bars are standard errors. p values were obtained by Student’s t test or One-way ANOVA. ns: not significant; ∗: p < 0.05; ∗∗: p < 0.01; ∗∗∗: p < 0.001; ∗∗∗∗: p < 0.0001.